Development of an innovative technology for producing short and long-lived insulin analogues, which are used for diabetes therapy. (Q78135): Difference between revisions
Jump to navigation
Jump to search
(Removed claim: summary (P836): In connection with the development of the production of insulin analogues, Bioton S.A. (hereinafter:Bioton, Company, Applicant) requests a funding for a research project on the development of a global unique pioneer installation for the production of insulin analogues short and long (hereinafter:Project) & ll;the first installation for the production of this type of product in Poland.The project involves research work aimed at creating a moder...) |
(Created claim: summary (P836): In connection with the development plans for the production of insulin analogues, Bioton S.A. (hereinafter: Bioton, Company, Applicant) applies for funding a research project concerning the development of a globally unique pioneering installation for the production of short and long-acting insulin analogues (hereafter: Project) – the first installation for the production of this type of products in Poland. The subject of the project is res...) |
||||||||||||||
| Property / summary | |||||||||||||||
In connection with the development plans for the production of insulin analogues, Bioton S.A. (hereinafter: Bioton, Company, Applicant) applies for funding a research project concerning the development of a globally unique pioneering installation for the production of short and long-acting insulin analogues (hereafter: Project) – the first installation for the production of this type of products in Poland. The subject of the project is research work aimed at creating a modern technological line for the production of active substances from the group of insulin analogues, based on unique and innovative solutions used at various stages of the production process (the Bioton own design). As a result of the work planned in the Project, a pilot line with parameters similar to the operational parameters will be created, in a configuration allowing the implementation of the Applicant’s own activity in the production environment (preparation for implementation and implementation is not part of the Project). The developed technology will respond to diagnosed market needs, mainly due to the increasing number of diabetes cases and from a limited number of producers of preparations that exploit the oligopoly character of the market, leading an aggressive pricing policy. Starting production and entering the Company as a new player in the insulin analogue segment (global sales) will allow to achieve a number of positive results mainly for patients. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). (English) | |||||||||||||||
| Property / summary: In connection with the development plans for the production of insulin analogues, Bioton S.A. (hereinafter: Bioton, Company, Applicant) applies for funding a research project concerning the development of a globally unique pioneering installation for the production of short and long-acting insulin analogues (hereafter: Project) – the first installation for the production of this type of products in Poland. The subject of the project is research work aimed at creating a modern technological line for the production of active substances from the group of insulin analogues, based on unique and innovative solutions used at various stages of the production process (the Bioton own design). As a result of the work planned in the Project, a pilot line with parameters similar to the operational parameters will be created, in a configuration allowing the implementation of the Applicant’s own activity in the production environment (preparation for implementation and implementation is not part of the Project). The developed technology will respond to diagnosed market needs, mainly due to the increasing number of diabetes cases and from a limited number of producers of preparations that exploit the oligopoly character of the market, leading an aggressive pricing policy. Starting production and entering the Company as a new player in the insulin analogue segment (global sales) will allow to achieve a number of positive results mainly for patients. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). (English) / rank | |||||||||||||||
Normal rank | |||||||||||||||
| Property / summary: In connection with the development plans for the production of insulin analogues, Bioton S.A. (hereinafter: Bioton, Company, Applicant) applies for funding a research project concerning the development of a globally unique pioneering installation for the production of short and long-acting insulin analogues (hereafter: Project) – the first installation for the production of this type of products in Poland. The subject of the project is research work aimed at creating a modern technological line for the production of active substances from the group of insulin analogues, based on unique and innovative solutions used at various stages of the production process (the Bioton own design). As a result of the work planned in the Project, a pilot line with parameters similar to the operational parameters will be created, in a configuration allowing the implementation of the Applicant’s own activity in the production environment (preparation for implementation and implementation is not part of the Project). The developed technology will respond to diagnosed market needs, mainly due to the increasing number of diabetes cases and from a limited number of producers of preparations that exploit the oligopoly character of the market, leading an aggressive pricing policy. Starting production and entering the Company as a new player in the insulin analogue segment (global sales) will allow to achieve a number of positive results mainly for patients. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). (English) / qualifier | |||||||||||||||
point in time: 14 October 2020
| |||||||||||||||
Revision as of 11:15, 14 October 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Development of an innovative technology for producing short and long-lived insulin analogues, which are used for diabetes therapy. |
Project in Poland financed by DG Regio |
Statements
20,988,427.57 zloty
0 references
50,684,467.63 zloty
0 references
41.41 percent
0 references
24 August 2016
0 references
30 November 2020
0 references
BIOTON SPÓŁKA AKCYJNA
0 references
52°32'46.3"N, 21°12'26.3"E
0 references
W związku z planami rozwoju produkcji analogów insuliny, BIOTON S.A. (dalej: BIOTON, Spółka, Wnioskodawca) wnioskuje o dofinansowanie projektu badawczego dotyczącego opracowania unikalnej w skali światowej, pionierskiej instalacji do produkcji analogów insuliny krótko i długodziałających (dalej: Projekt) – pierwszej instalacji do produkcji tego rodzaju produktów w Polsce. Przedmiotem Projektu są prace badawcze mające na celu stworzenie nowoczesnej linii technologicznej z przeznaczeniem do wytwarzania substancji czynnych z grupy analogów insuliny, opartej na unikatowych i nowatorskich rozwiązaniach, stosowanych na różnych etapach procesu produkcyjnego (projekt własny BIOTONU). W rezultacie zaplanowanych w Projekcie prac powstanie linia pilotażowa o parametrach zbliżonych do operacyjnych, w konfiguracji pozwalającej na wdrożenie w działalności własnej Wnioskodawcy, w posiadanym przez niego środowisku produkcyjnym (przygotowanie do wdrożenia oraz wdrożenie nie jest elementem Projektu). Opracowana technologia będzie stanowić odpowiedź na zdiagnozowane potrzeby rynkowe, wynikające przede wszystkim z rosnącej liczby zachorowań na cukrzycę oraz z ograniczonej liczby producentów preparatów, którzy wykorzystują oligopolowy charakter rynku, prowadząc agresywną politykę cenową. Rozpoczęcie produkcji i wejście Spółki jako nowego gracza w segmencie analogów insuliny (sprzedaż ogólnoświatowa) pozwoli na osiągnięcie szeregu pozytywnych rezultatów przede wszystkim dla pacjentów. Numer_referencyjny_programu_pomocowego: SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014). (Polish)
0 references
In connection with the development plans for the production of insulin analogues, Bioton S.A. (hereinafter: Bioton, Company, Applicant) applies for funding a research project concerning the development of a globally unique pioneering installation for the production of short and long-acting insulin analogues (hereafter: Project) – the first installation for the production of this type of products in Poland. The subject of the project is research work aimed at creating a modern technological line for the production of active substances from the group of insulin analogues, based on unique and innovative solutions used at various stages of the production process (the Bioton own design). As a result of the work planned in the Project, a pilot line with parameters similar to the operational parameters will be created, in a configuration allowing the implementation of the Applicant’s own activity in the production environment (preparation for implementation and implementation is not part of the Project). The developed technology will respond to diagnosed market needs, mainly due to the increasing number of diabetes cases and from a limited number of producers of preparations that exploit the oligopoly character of the market, leading an aggressive pricing policy. Starting production and entering the Company as a new player in the insulin analogue segment (global sales) will allow to achieve a number of positive results mainly for patients. Reference number of the aid programme: SA.41471(2015/X) Purpose of public aid: Article 25 of EC Regulation No 651/2014 of 17 June 2014 declaring certain types of aid compatible with the internal market in the application of Articles 107 and 108 of the Treaty (OJ L. I'm sorry. EU L 187/1 of 26.06.2014). (English)
14 October 2020
0 references
Identifiers
POIR.01.01.01-00-0579/16
0 references